Pub Date : 2024-03-01DOI: 10.1016/j.joim.2024.02.002
Nora Selena Eberli, Ludivine Colas, Anne Gimalac
Meal timing plays a crucial role for cardiometabolic health, given the circadian regulation of cardiometabolic function. However, to the best of our knowledge, no concept of meal timing exists in traditional European medicine (TEM). Therefore, in this narrative review, we aim to define the optimal time slot for energy intake and optimal energy distribution throughout the day in a context of TEM and explore further implications. By reviewing literature published between 2002 and 2022, we found that optimal timing for energy intake may be between 06:00 and 09:00, 12:00 and 14:00, and between 15:00 and 18:00, with high energy breakfast, medium energy lunch and low energy dinner and possibly further adjustments according to one’s chronotype and genetics. Also, timing and distribution of energy intake may serve as a novel therapeutic strategy to optimize coction, a concept describing digestion and metabolism in TEM.
Please cite this article as: Eberli NS, Colas L, Gimalac A. Chrononutrition in traditional European medicine—Ideal meal timing for cardiometabolic health promotion. J Integr Med. 2024; 22(2);115–125.
鉴于昼夜节律对心脏代谢功能的调节作用，进餐时间对心脏代谢健康起着至关重要的作用。然而，据我们所知，欧洲传统医学（TEM）中并不存在进餐时间的概念。因此，在这篇叙述性综述中，我们的目的是在 TEM 的背景下定义能量摄入的最佳时间段和全天的最佳能量分配，并探讨进一步的影响。通过回顾 2002 年至 2022 年间发表的文献，我们发现能量摄入的最佳时间段可能是 6:00 至 9:00、12:00 至 14:00、15:00 至 18:00，其中早餐能量高、午餐能量适中、晚餐能量低，并可能根据个人的时间型和遗传学做进一步调整。此外，能量摄入的时间和分布可作为一种新的治疗策略，优化TEM中的消化和新陈代谢。本文引用如前：Eberli NS, Colas L, Gimalac A. 欧洲传统医学中的慢性营养--促进心脏代谢健康的理想进餐时间。J Integr Med.2024; Epub ahead of print.
{"title":"Chrononutrition in traditional European medicine—Ideal meal timing for cardiometabolic health promotion","authors":"Nora Selena Eberli, Ludivine Colas, Anne Gimalac","doi":"10.1016/j.joim.2024.02.002","DOIUrl":"10.1016/j.joim.2024.02.002","url":null,"abstract":"<div><p>Meal timing plays a crucial role for cardiometabolic health, given the circadian regulation of cardiometabolic function. However, to the best of our knowledge, no concept of meal timing exists in traditional European medicine (TEM). Therefore, in this narrative review, we aim to define the optimal time slot for energy intake and optimal energy distribution throughout the day in a context of TEM and explore further implications. By reviewing literature published between 2002 and 2022, we found that optimal timing for energy intake may be between 06:00 and 09:00, 12:00 and 14:00, and between 15:00 and 18:00, with high energy breakfast, medium energy lunch and low energy dinner and possibly further adjustments according to one’s chronotype and genetics. Also, timing and distribution of energy intake may serve as a novel therapeutic strategy to optimize coction, a concept describing digestion and metabolism in TEM.</p><p>Please cite this article as: Eberli NS, Colas L, Gimalac A. Chrononutrition in traditional European medicine—Ideal meal timing for cardiometabolic health promotion. <em>J Integr Med</em>. 2024; 22(2);115–125.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 2","pages":"Pages 115-125"},"PeriodicalIF":4.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140111924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-01DOI: 10.1016/j.joim.2024.03.001
Lin-yan Jiang , Jun Tian , Ya-nan Yang , Shao-hui Jia , Qing Shu
Obesity is defined as abnormal or excessive fat accumulation that may impair health. Obesity is associated with numerous pathological changes including insulin resistance, fatty liver, hyperlipidemias, and other obesity-related diseases. These comorbidities comprise a significant public health threat. Existing anti-obesity drugs have been limited by side effects that include depression, suicidal thoughts, cardiovascular complications and stroke. Acupuncture treatment has been shown to be effective for treating obesity and obesity-related conditions, while avoiding side effects. However, the mechanisms of acupuncture in treating obesity-related diseases, especially its effect on neural circuits, are not well understood. A growing body of research has studied acupuncture’s effects on the endocrine system and other mechanisms related to the regulation of neural circuits. In this article, recent research that was relevant to the use of acupuncture to treat obesity and obesity-related diseases through the neuroendocrine system, as well as some neural circuits involved, was summarized. Based on this, acupuncture’s potential ability to regulate neural circuits and its mechanisms of action in the endocrine system were reviewed, leading to a deeper mechanistic understanding of acupuncture’s effects and providing insight and direction for future research about obesity.
Please cite this article as: Jiang LY, Tian J, Yang YN, Jia SH, Shu Q. Acupuncture for obesity and related diseases: insight for regulating neural circuit. J Integr Med. 2024; 22(2): 93–101.
{"title":"Acupuncture for obesity and related diseases: Insight for regulating neural circuit","authors":"Lin-yan Jiang , Jun Tian , Ya-nan Yang , Shao-hui Jia , Qing Shu","doi":"10.1016/j.joim.2024.03.001","DOIUrl":"10.1016/j.joim.2024.03.001","url":null,"abstract":"<div><p>Obesity is defined as abnormal or excessive fat accumulation that may impair health. Obesity is associated with numerous pathological changes including insulin resistance, fatty liver, hyperlipidemias, and other obesity-related diseases. These comorbidities comprise a significant public health threat. Existing anti-obesity drugs have been limited by side effects that include depression, suicidal thoughts, cardiovascular complications and stroke. Acupuncture treatment has been shown to be effective for treating obesity and obesity-related conditions, while avoiding side effects. However, the mechanisms of acupuncture in treating obesity-related diseases, especially its effect on neural circuits, are not well understood. A growing body of research has studied acupuncture’s effects on the endocrine system and other mechanisms related to the regulation of neural circuits. In this article, recent research that was relevant to the use of acupuncture to treat obesity and obesity-related diseases through the neuroendocrine system, as well as some neural circuits involved, was summarized. Based on this, acupuncture’s potential ability to regulate neural circuits and its mechanisms of action in the endocrine system were reviewed, leading to a deeper mechanistic understanding of acupuncture’s effects and providing insight and direction for future research about obesity.</p><p>Please cite this article as: Jiang LY, Tian J, Yang YN, Jia SH, Shu Q. Acupuncture for obesity and related diseases: insight for regulating neural circuit. <em>J Integr Med</em>. 2024; 22(2): 93–101.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 2","pages":"Pages 93-101"},"PeriodicalIF":4.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2095496424000256/pdfft?md5=58d62d8eaa2d4d391ae8fb9d76c12368&pid=1-s2.0-S2095496424000256-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140075301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-01DOI: 10.1016/j.joim.2024.01.008
Zhen-yu Ma , Shu-ping Yang , Ying Li , Tian-tian Xu , Ya-lin Yang , Hui-yong Yang , Heng-bing Li , Le-jin Zhou , Yong Diao , Su-yun Li
<div><h3>Background</h3><p>Red yeast rice (RYR), a natural lipid-lowering agent, is widely used in clinical practice. However, the existing meta-analyses concerning the safety of RYR preparations have yielded inconsistent results, and the credibility of the evidence has not been quantified.</p></div><div><h3>Objective</h3><p>This study was designed to evaluate the existing evidence and offer a comprehensive understanding of the associations between the use of RYR preparations and various adverse health outcomes.</p></div><div><h3>Search strategy</h3><p>Seven literature databases were searched from inception to May 5, 2023, using medical subject headings and free-text terms (e.g., “red yeast rice,” “<em>Xuezhikang</em>,” and “<em>Zhibitai</em>”).</p></div><div><h3>Inclusion criteria</h3><p>Meta-analyses that investigated and quantitatively estimated associations between the use of RYR preparations and adverse health outcomes were included in this study.</p></div><div><h3>Data extraction and analysis</h3><p>Two researchers independently extracted data using a standardized data collection table; any disagreements were resolved by consulting a third researcher. Based on the participant, intervention, comparator and outcome (PICO) framework in each eligible meta-analysis, a series of unique associations between the use of RYR preparations and adverse health outcomes were determined. The associations’ effect estimates were re-evaluated using random-effect models.</p></div><div><h3>Results</h3><p>Fifteen meta-analyses, comprising 186 (164 unique) randomized controlled trials, were identified. Based on A MeaSurement Tool to Assess Systematic Reviews version 2, 3 (20%) and 12 (80%) of these meta-analyses had low and critically low confidence, respectively. A total of 61 unique associations between the use of RYR preparations and adverse health outcomes were extracted from eligible meta-analyses. Based on the random-effect models, 10 (16.4%) associations indicated a significant protective effect of RYR preparations against adverse health outcomes, while 5 (8.2%) indicated an increased risk of adverse health outcomes related to uric acid, alanine transaminase and aspartate transaminase levels. The other 46 (75.4%) associations showed no significant difference between the use of RYR preparations and control treatments. Regarding the credibility of the evidence, 21 (34.4%), 34 (55.7%) and 6 (9.8%) associations showed moderate, low and very low credibility, respectively.</p></div><div><h3>Conclusion</h3><p>The evidence examined in this study suggests that RYR preparations are safe; however, the credibility of the evidence was not high. Further high-quality evidence is required.</p><p>Please cite this article as: Ma ZY, Yang SP, Li Y, Xu TT, Yang YL, Yang HY, Li HB, Zhou LJ, Diao Y, Li SY. Associations between the use of red yeast rice preparations and adverse health outcomes: An umbrella review of meta-analyses of randomized controlled trials. <em>J Integr Med
背景红曲米（RYR）是一种天然降血脂药物，被广泛应用于临床实践。本研究旨在评估现有证据，并全面了解使用红酵母米制剂与各种不良健康结果之间的关联。检索策略使用医学主题词和自由文本词（如 "红酵母米"、"雪芝康 "和 "知必泰"）检索了七个文献数据库，检索期从开始到 2023 年 5 月 5 日、"纳入标准本研究纳入了调查和定量估计使用红曲制剂与不良健康后果之间相关性的元分析。数据提取和分析两名研究人员使用标准化数据收集表独立提取数据；任何分歧均通过咨询第三名研究人员来解决。根据每项符合条件的荟萃分析中的参与者、干预措施、比较者和结果（PICO）框架，确定了使用 RYR 制剂与不良健康结果之间的一系列独特关联。使用随机效应模型对这些关联的效应估计值进行了重新评估。结果确定了 15 项元分析，包括 186 项随机对照试验（164 项唯一试验）。根据系统综述评估工具（A MeaSurement Tool to Assess Systematic Reviews）第 2 版，这些荟萃分析中分别有 3 项（20%）和 12 项（80%）置信度较低和极低。从符合条件的荟萃分析中，共提取了 61 项使用 RYR 制剂与不良健康结果之间的独特关联。根据随机效应模型，10 项（16.4%）关联表明 RYR 制剂对不良健康结果具有显著的保护作用，5 项（8.2%）关联表明与尿酸、丙氨酸转氨酶和天冬氨酸转氨酶水平有关的不良健康结果的风险增加。其他 46 项（75.4%）关联显示，使用 RYR 制剂与对照治疗之间没有显著差异。关于证据的可信度，21 项（34.4%）、34 项（55.7%）和 6 项（9.8%）分别显示出中等、低和极低的可信度。本文引用如前：Ma ZY, Yang SP, Li Y, Xu TT, Yang YL, Yang HY, Li HB, Zhou LJ, Diao Y, Li SY.使用红曲米制剂与不良健康后果之间的关系：随机对照试验荟萃分析综述》。J Integr Med.2023; Epub ahead of print.
{"title":"Associations between the use of red yeast rice preparations and adverse health outcomes: An umbrella review of meta-analyses of randomized controlled trials","authors":"Zhen-yu Ma , Shu-ping Yang , Ying Li , Tian-tian Xu , Ya-lin Yang , Hui-yong Yang , Heng-bing Li , Le-jin Zhou , Yong Diao , Su-yun Li","doi":"10.1016/j.joim.2024.01.008","DOIUrl":"10.1016/j.joim.2024.01.008","url":null,"abstract":"<div><h3>Background</h3><p>Red yeast rice (RYR), a natural lipid-lowering agent, is widely used in clinical practice. However, the existing meta-analyses concerning the safety of RYR preparations have yielded inconsistent results, and the credibility of the evidence has not been quantified.</p></div><div><h3>Objective</h3><p>This study was designed to evaluate the existing evidence and offer a comprehensive understanding of the associations between the use of RYR preparations and various adverse health outcomes.</p></div><div><h3>Search strategy</h3><p>Seven literature databases were searched from inception to May 5, 2023, using medical subject headings and free-text terms (e.g., “red yeast rice,” “<em>Xuezhikang</em>,” and “<em>Zhibitai</em>”).</p></div><div><h3>Inclusion criteria</h3><p>Meta-analyses that investigated and quantitatively estimated associations between the use of RYR preparations and adverse health outcomes were included in this study.</p></div><div><h3>Data extraction and analysis</h3><p>Two researchers independently extracted data using a standardized data collection table; any disagreements were resolved by consulting a third researcher. Based on the participant, intervention, comparator and outcome (PICO) framework in each eligible meta-analysis, a series of unique associations between the use of RYR preparations and adverse health outcomes were determined. The associations’ effect estimates were re-evaluated using random-effect models.</p></div><div><h3>Results</h3><p>Fifteen meta-analyses, comprising 186 (164 unique) randomized controlled trials, were identified. Based on A MeaSurement Tool to Assess Systematic Reviews version 2, 3 (20%) and 12 (80%) of these meta-analyses had low and critically low confidence, respectively. A total of 61 unique associations between the use of RYR preparations and adverse health outcomes were extracted from eligible meta-analyses. Based on the random-effect models, 10 (16.4%) associations indicated a significant protective effect of RYR preparations against adverse health outcomes, while 5 (8.2%) indicated an increased risk of adverse health outcomes related to uric acid, alanine transaminase and aspartate transaminase levels. The other 46 (75.4%) associations showed no significant difference between the use of RYR preparations and control treatments. Regarding the credibility of the evidence, 21 (34.4%), 34 (55.7%) and 6 (9.8%) associations showed moderate, low and very low credibility, respectively.</p></div><div><h3>Conclusion</h3><p>The evidence examined in this study suggests that RYR preparations are safe; however, the credibility of the evidence was not high. Further high-quality evidence is required.</p><p>Please cite this article as: Ma ZY, Yang SP, Li Y, Xu TT, Yang YL, Yang HY, Li HB, Zhou LJ, Diao Y, Li SY. Associations between the use of red yeast rice preparations and adverse health outcomes: An umbrella review of meta-analyses of randomized controlled trials. <em>J Integr Med","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 2","pages":"Pages 126-136"},"PeriodicalIF":4.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139662922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-01DOI: 10.1016/j.joim.2024.03.004
Yi Zhang , Si-jing Liu
Atherosclerosis is a leading cause of mortality and morbidity worldwide. Despite the challenges in managing atherosclerosis, researchers continue to investigate new treatments and complementary therapies. Cordyceps is a traditional Chinese medicine that has recently gained attention as a potential therapeutic agent for atherosclerosis. Numerous studies have demonstrated the effectiveness of cordyceps in treating atherosclerosis through various pharmacological actions, including anti-inflammatory and antioxidant activities, lowering cholesterol, inhibiting platelet aggregation, and modulating apoptosis or autophagy in vascular endothelial cells. Notably, the current misuse of the terms cordyceps and Ophiocordyceps sinensis has caused confusion among researchers, and complicated the current academic research on cordyceps. This review focuses on the chemical composition, pharmacological actions, and underlying mechanisms contributing to the anti-atherosclerotic effects of cordyceps and the mycelium of Ophiocordyceps spp. This review provides a resource for the research on the development of new drugs for atherosclerosis from cordyceps.
Please cite this article as: Zhang Y, Liu SJ. Cordyceps as potential therapeutic agents for atherosclerosis. J Integr Med. 2024; 22(2): 102–114.
{"title":"Cordyceps as potential therapeutic agents for atherosclerosis","authors":"Yi Zhang , Si-jing Liu","doi":"10.1016/j.joim.2024.03.004","DOIUrl":"10.1016/j.joim.2024.03.004","url":null,"abstract":"<div><p>Atherosclerosis is a leading cause of mortality and morbidity worldwide. Despite the challenges in managing atherosclerosis, researchers continue to investigate new treatments and complementary therapies. Cordyceps is a traditional Chinese medicine that has recently gained attention as a potential therapeutic agent for atherosclerosis. Numerous studies have demonstrated the effectiveness of cordyceps in treating atherosclerosis through various pharmacological actions, including anti-inflammatory and antioxidant activities, lowering cholesterol, inhibiting platelet aggregation, and modulating apoptosis or autophagy in vascular endothelial cells. Notably, the current misuse of the terms cordyceps and <em>Ophiocordyceps sinensis</em> has caused confusion among researchers, and complicated the current academic research on cordyceps. This review focuses on the chemical composition, pharmacological actions, and underlying mechanisms contributing to the anti-atherosclerotic effects of cordyceps and the mycelium of <em>Ophiocordyceps</em> spp. This review provides a resource for the research on the development of new drugs for atherosclerosis from cordyceps.</p><p>Please cite this article as: Zhang Y, Liu SJ. Cordyceps as potential therapeutic agents for atherosclerosis. <em>J Integr Med</em>. 2024; 22(2): 102–114.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 2","pages":"Pages 102-114"},"PeriodicalIF":4.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140075180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-01DOI: 10.1016/j.joim.2024.02.001
Bizhar Ahmed Tayeb , Ikhwan Yuda Kusuma , Alaa A.M. Osman , Renáta Minorics
Background
The field of personalized medicine has gained increasing attention in cancer care, with the aim of tailoring treatment strategies to individual patients for improved outcomes. Herbal medicine, with its long-standing historical use and extensive bioactive compounds, offers a rich source of potential treatments for various diseases, including cancer.
Objective
To provide an overview of the current knowledge and evidence associated with incorporating herbal compounds into precision medicine strategies for cancer diseases. Additionally, to explore the general characteristics of the studies included in the analysis, focusing on their key features and trends.
Search strategy
A comprehensive literature search was conducted from multiple online databases, including PubMed, Scopus, Web of Science, and CINAHL-EBSCO. The search strategy was designed to identify studies related to personalized cancer medicine and herbal interventions.
Inclusion criteria
Publications pertaining to cancer research conducted through in vitro, in vivo, and clinical studies, employing natural products were included in this review.
Data extraction and analysis
Two review authors independently applied inclusion and inclusion criteria, data extraction, and assessments of methodological quality. The quality assessment and biases of the studies were evaluated based on modified Jadad scales. A detailed quantitative summary of the included studies is presented, providing a comprehensive description of their key features and findings.
Results
A total of 121 studies were included in this review for analysis. Some of them were considered as comprehensive experimental investigations both in vitro and in vivo. The majority (n = 85) of the studies included in this review were conducted in vitro, with 44 of them specifically investigating the effects of herbal medicine on animal models. Additionally, 7 articles with a combined sample size of 31,271 patients, examined the impact of herbal medicine in clinical settings.
Conclusion
Personalized medication can optimize the use of herbal medicine in cancer treatment by considering individual patient factors such as genetics, medical history, and other treatments. Additionally, active phytochemicals found in herbs have shown potential for inhibiting cancer cell growth and inducing apoptosis, making them a promising area of research in preclinical and clinical investigations.
Please cite this article as: Tayeb BA, Kusuma IY, Osman AAM, Minorics R. Herbal compounds as promising therapeutic agents in precision medicine strategies for cancer: A systematic review. J Integr Med. 2024; 22(2): 137–162.
{"title":"Herbal compounds as promising therapeutic agents in precision medicine strategies for cancer: A systematic review","authors":"Bizhar Ahmed Tayeb , Ikhwan Yuda Kusuma , Alaa A.M. Osman , Renáta Minorics","doi":"10.1016/j.joim.2024.02.001","DOIUrl":"10.1016/j.joim.2024.02.001","url":null,"abstract":"<div><h3>Background</h3><p>The field of personalized medicine has gained increasing attention in cancer care, with the aim of tailoring treatment strategies to individual patients for improved outcomes. Herbal medicine, with its long-standing historical use and extensive bioactive compounds, offers a rich source of potential treatments for various diseases, including cancer.</p></div><div><h3>Objective</h3><p>To provide an overview of the current knowledge and evidence associated with incorporating herbal compounds into precision medicine strategies for cancer diseases. Additionally, to explore the general characteristics of the studies included in the analysis, focusing on their key features and trends.</p></div><div><h3>Search strategy</h3><p>A comprehensive literature search was conducted from multiple online databases, including PubMed, Scopus, Web of Science, and CINAHL-EBSCO. The search strategy was designed to identify studies related to personalized cancer medicine and herbal interventions.</p></div><div><h3>Inclusion criteria</h3><p>Publications pertaining to cancer research conducted through in vitro, in vivo, and clinical studies, employing natural products were included in this review.</p></div><div><h3>Data extraction and analysis</h3><p>Two review authors independently applied inclusion and inclusion criteria, data extraction, and assessments of methodological quality. The quality assessment and biases of the studies were evaluated based on modified Jadad scales. A detailed quantitative summary of the included studies is presented, providing a comprehensive description of their key features and findings.</p></div><div><h3>Results</h3><p>A total of 121 studies were included in this review for analysis. Some of them were considered as comprehensive experimental investigations both in vitro and in vivo. The majority (<em>n</em> = 85) of the studies included in this review were conducted in vitro, with 44 of them specifically investigating the effects of herbal medicine on animal models. Additionally, 7 articles with a combined sample size of 31,271 patients, examined the impact of herbal medicine in clinical settings.</p></div><div><h3>Conclusion</h3><p>Personalized medication can optimize the use of herbal medicine in cancer treatment by considering individual patient factors such as genetics, medical history, and other treatments. Additionally, active phytochemicals found in herbs have shown potential for inhibiting cancer cell growth and inducing apoptosis, making them a promising area of research in preclinical and clinical investigations.</p><p>Please cite this article as: Tayeb BA, Kusuma IY, Osman AAM, Minorics R. Herbal compounds as promising therapeutic agents in precision medicine strategies for cancer: A systematic review. <em>J Integr Med</em>. 2024; 22(2): 137–162.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 2","pages":"Pages 137-162"},"PeriodicalIF":4.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140016664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-01DOI: 10.1016/j.joim.2024.03.006
Meng Li , Yang Zhou , Hui Zhu , Lie-ming Xu , Jian Ping
Objective
This study explores the mechanism of action of Danhongqing formula (DHQ), a compound-based Chinese medicine formula, in the treatment of cholestatic liver fibrosis.
Methods
In vivo experiments were conducted using 8-week-old multidrug resistance protein 2 knockout (Mdr2-/-) mice as an animal model of cholestatic liver fibrosis. DHQ was administered orally for 8 weeks, and its impact on cholestatic liver fibrosis was evaluated by assessing liver function, liver histopathology, and the expression of liver fibrosis-related proteins. Real-time polymerase chain reaction, Western blot, immunohistochemistry and other methods were used to observe the effects of DHQ on long non-coding RNA H19 (H19) and signal transducer and activator of transcription 3 (STAT3) phosphorylation in the liver tissue of Mdr2-/- mice. In addition, cholangiocytes and hepatic stellate cells (HSCs) were cultured in vitro to measure the effects of bile acids on cholangiocyte injury and H19 expression. Cholangiocytes overexpressing H19 were constructed, and a conditioned medium containing H19 was collected to measure its effects on STAT3 protein expression and cell activation. The intervention effect of DHQ on these processes was also investigated. HSCs overexpressing H19 were constructed to measure the impact of H19 on cell activation and assess the intervention effect of DHQ.
Results
DHQ alleviated liver injury, ductular reaction, and fibrosis in Mdr2-/- mice, and inhibited H19 expression, STAT3 expression and STAT3 phosphorylation. This formula also reduced hydrophobic bile acid-induced cholangiocyte injury and the upregulation of H19, inhibited the activation of HSCs induced by cholangiocyte-derived conditioned medium, and decreased the expression of activation markers in HSCs. The overexpression of H19 in a human HSC line confirmed that H19 promoted STAT3 phosphorylation and HSC activation, and DHQ was able to successfully inhibit these effects.
Conclusion
DHQ effectively alleviated spontaneous cholestatic liver fibrosis in Mdr2-/- mice by inhibiting H19 upregulation in cholangiocytes and preventing the inhibition of STAT3 phosphorylation in HSC, thereby suppressing cell activation.
Please cite this article as: Li M, Zhou Y, Zhu H, Xu LM, Ping J. Danhongqing formula alleviates cholestatic liver fibrosis by downregulating long non-coding RNA H19 derived from cholangiocytes and inhibiting hepatic stellate cell activation. J Integr Med. 2024; 22(2): 188–198.
目的：探讨复方中药丹红清方治疗胆汁淤积性肝纤维化的作用机制：本研究探讨复方中药丹红清方（DHQ）治疗胆汁淤积性肝纤维化的作用机制：以8周龄多耐药蛋白2基因敲除（Mdr2-/-）小鼠为胆汁淤积性肝纤维化动物模型进行体内实验。口服DHQ 8周，通过评估肝功能、肝组织病理学和肝纤维化相关蛋白的表达来评价DHQ对胆汁淤积性肝纤维化的影响。采用实时聚合酶链反应、Western印迹、免疫组化等方法观察了DHQ对Mdr2-/-小鼠肝组织中长非编码RNA H19（H19）和信号转导和激活剂3（STAT3）磷酸化的影响。此外，还对胆管细胞和肝星状细胞（HSCs）进行了体外培养，以测定胆汁酸对胆管细胞损伤和 H19 表达的影响。构建了过表达 H19 的胆管细胞，并收集了含有 H19 的条件培养基，以测量其对 STAT3 蛋白表达和细胞活化的影响。同时还研究了 DHQ 对这些过程的干预作用。构建了过表达H19的造血干细胞，以测量H19对细胞活化的影响并评估DHQ的干预效果：结果：DHQ减轻了Mdr2-/-小鼠的肝损伤、导管反应和纤维化，抑制了H19表达、STAT3表达和STAT3磷酸化。该配方还能减轻疏水胆酸诱导的胆管细胞损伤和H19的上调，抑制胆管细胞源性条件培养基诱导的造血干细胞活化，降低造血干细胞活化标志物的表达。在人造血干细胞系中过表达H19证实，H19能促进STAT3磷酸化和造血干细胞活化，而DHQ能成功抑制这些效应：结论：DHQ通过抑制胆管细胞中H19的上调和防止抑制造血干细胞中STAT3磷酸化，从而抑制细胞活化，有效缓解了Mdr2-/-小鼠自发性胆汁淤积性肝纤维化。本文引用如前Li M, Zhou Y, Zhu H, Xu LM, Ping J. Danhongqing formula alleviates cholestatic liver fibrosis by downregulating long non-coding RNA H19 derived from cholangiocytes and inhibiting hepatic stellate cell activation.J Integr Med.2024; Epub ahead of print.
{"title":"Danhongqing formula alleviates cholestatic liver fibrosis by downregulating long non-coding RNA H19 derived from cholangiocytes and inhibiting hepatic stellate cell activation","authors":"Meng Li , Yang Zhou , Hui Zhu , Lie-ming Xu , Jian Ping","doi":"10.1016/j.joim.2024.03.006","DOIUrl":"10.1016/j.joim.2024.03.006","url":null,"abstract":"<div><h3>Objective</h3><p>This study explores the mechanism of action of Danhongqing formula (DHQ), a compound-based Chinese medicine formula, in the treatment of cholestatic liver fibrosis.</p></div><div><h3>Methods</h3><p>In vivo experiments were conducted using 8-week-old <em>multidrug resistance protein 2</em> knockout (<em>Mdr2<sup>-/-</sup></em>) mice as an animal model of cholestatic liver fibrosis. DHQ was administered orally for 8 weeks, and its impact on cholestatic liver fibrosis was evaluated by assessing liver function, liver histopathology, and the expression of liver fibrosis-related proteins. Real-time polymerase chain reaction, Western blot, immunohistochemistry and other methods were used to observe the effects of DHQ on long non-coding RNA <em>H19</em> (<em>H19</em>) and signal transducer and activator of transcription 3 (STAT3) phosphorylation in the liver tissue of <em>Mdr2<sup>-/-</sup></em> mice. In addition, cholangiocytes and hepatic stellate cells (HSCs) were cultured in vitro to measure the effects of bile acids on cholangiocyte injury and <em>H19</em> expression. Cholangiocytes overexpressing <em>H19</em> were constructed, and a conditioned medium containing <em>H19</em> was collected to measure its effects on STAT3 protein expression and cell activation. The intervention effect of DHQ on these processes was also investigated. HSCs overexpressing <em>H19</em> were constructed to measure the impact of <em>H19</em> on cell activation and assess the intervention effect of DHQ.</p></div><div><h3>Results</h3><p>DHQ alleviated liver injury, ductular reaction, and fibrosis in <em>Mdr2<sup>-/-</sup></em> mice, and inhibited <em>H19</em> expression, STAT3 expression and STAT3 phosphorylation. This formula also reduced hydrophobic bile acid-induced cholangiocyte injury and the upregulation of <em>H19</em>, inhibited the activation of HSCs induced by cholangiocyte-derived conditioned medium, and decreased the expression of activation markers in HSCs. The overexpression of <em>H19</em> in a human HSC line confirmed that <em>H19</em> promoted STAT3 phosphorylation and HSC activation, and DHQ was able to successfully inhibit these effects.</p></div><div><h3>Conclusion</h3><p>DHQ effectively alleviated spontaneous cholestatic liver fibrosis in <em>Mdr2<sup>-/-</sup></em> mice by inhibiting <em>H19</em> upregulation in cholangiocytes and preventing the inhibition of STAT3 phosphorylation in HSC, thereby suppressing cell activation.</p><p>Please cite this article as: Li M, Zhou Y, Zhu H, Xu LM, Ping J. Danhongqing formula alleviates cholestatic liver fibrosis by downregulating long non-coding RNA <em>H19</em> derived from cholangiocytes and inhibiting hepatic stellate cell activation. <em>J Integr Med.</em> 2024; 22(2): 188–198.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 2","pages":"Pages 188-198"},"PeriodicalIF":4.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140111925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-01DOI: 10.1016/j.joim.2024.03.005
Peng Wang , Jing Hong , Zhu-qian Tang , Bi-zhen Gong , Xiao-rong Qi , Han Jiang , Bo Pan , Qi Chen
Objective
The efficacy of medications for Parkinson’s disease (PD) tend to decline over time, which has a serious impact on patients’ health and quality of life. To some extent, traditional Chinese medicine (TCM) can resolve the distressing problem of ineffective dopaminergic medication in PD patients. The purpose of this study was to investigate the attitude, acceptance, and independent predictors of TCM in PD patients admitted to the outpatient department of a tertiary hospital.
Methods
A cross-sectional study of PD patients was conducted in the outpatient department of a large tertiary hospital in Beijing from March 2022 to June 2023. A self-report questionnaire was developed to investigate PD patients’ attitudes and acceptance of TCM based on the questionnaire. Multivariate logistic regression analyses were also performed to further clarify the independent predictors influencing patients’ adoption of TCM therapy.
Results
A total of 397 patients completed the questionnaire, of which 78.09% were willing to be treated with TCM and 21.91% indicated that they were not willing to use TCM. Multifactorial logistic regression analysis showed that several parameters were correlated with a patient’s willingness to include TCM in their therapeutic regime. These included education level of a bachelor’s degree (odds ratio [OR) = 8.554; 95% confidence interval [CI]: 4.112–17.794; P < 0.001, vs junior high school education), living in an urban setting (OR = 8.022; 95% CI: 4.577–14.060; P < 0.001, vs rural), having other underlying diseases (OR = 5.126; 95% CI: 3.078–8.537; P < 0.001, vs none), having previously used TCM (OR = 3.083; 95% CI: 1.852–5.134; P < 0.001, vs not used), believing that TCM therapy is safe (OR = 3.530; 95% CI: 1.446–8.616; P = 0.006, vs not thought), believing that TCM therapy is effective (OR = 3.859; 95% CI: 1.482–10.047; P = 0.006, vs not understood), and being willing to discuss ongoing TCM therapy with an attending physician (OR = 62.468; 95% CI: 30.350–128.574; P < 0.001, vs not informed).
Conclusion
This study initially investigated the acceptance, attitude, and independent predictors of TCM use among PD patients. To expand the prevalence of TCM use among patients with PD, we recommend to broadening the public outreach for TCM via contemporary means of Internet and broadcast communication, enhancing access to TCM services in rural communities, and strengthening the communication between doctors and patients.
Please cite this article as: Wang P, Hong J, Tang ZQ, Gong BZ, Qi XR, Jiang H, Pan B, Chen Q. The acceptance of traditional Chinese medicine among patients with Parkinson’s disease: A hospital survey. J Integr Med. 2024; 22(2): 180–187.
{"title":"The acceptance of traditional Chinese medicine among patients with Parkinson’s disease: A hospital survey","authors":"Peng Wang , Jing Hong , Zhu-qian Tang , Bi-zhen Gong , Xiao-rong Qi , Han Jiang , Bo Pan , Qi Chen","doi":"10.1016/j.joim.2024.03.005","DOIUrl":"10.1016/j.joim.2024.03.005","url":null,"abstract":"<div><h3>Objective</h3><p>The efficacy of medications for Parkinson’s disease (PD) tend to decline over time, which has a serious impact on patients’ health and quality of life. To some extent, traditional Chinese medicine (TCM) can resolve the distressing problem of ineffective dopaminergic medication in PD patients. The purpose of this study was to investigate the attitude, acceptance, and independent predictors of TCM in PD patients admitted to the outpatient department of a tertiary hospital.</p></div><div><h3>Methods</h3><p>A cross-sectional study of PD patients was conducted in the outpatient department of a large tertiary hospital in Beijing from March 2022 to June 2023. A self-report questionnaire was developed to investigate PD patients’ attitudes and acceptance of TCM based on the questionnaire. Multivariate logistic regression analyses were also performed to further clarify the independent predictors influencing patients’ adoption of TCM therapy.</p></div><div><h3>Results</h3><p>A total of 397 patients completed the questionnaire, of which 78.09% were willing to be treated with TCM and 21.91% indicated that they were not willing to use TCM. Multifactorial logistic regression analysis showed that several parameters were correlated with a patient’s willingness to include TCM in their therapeutic regime. These included education level of a bachelor’s degree (odds ratio [OR) = 8.554; 95% confidence interval [CI]: 4.112–17.794; <em>P</em> < 0.001, <em>vs</em> junior high school education), living in an urban setting (OR = 8.022; 95% CI: 4.577–14.060; <em>P</em> < 0.001, <em>vs</em> rural), having other underlying diseases (OR = 5.126; 95% CI: 3.078–8.537; <em>P</em> < 0.001, <em>vs</em> none), having previously used TCM (OR = 3.083; 95% CI: 1.852–5.134; <em>P</em> < 0.001, <em>vs</em> not used), believing that TCM therapy is safe (OR = 3.530; 95% CI: 1.446–8.616; <em>P</em> = 0.006, <em>vs</em> not thought), believing that TCM therapy is effective (OR = 3.859; 95% CI: 1.482–10.047; <em>P</em> = 0.006, <em>vs</em> not understood), and being willing to discuss ongoing TCM therapy with an attending physician (OR = 62.468; 95% CI: 30.350–128.574; <em>P</em> < 0.001, <em>vs</em> not informed).</p></div><div><h3>Conclusion</h3><p>This study initially investigated the acceptance, attitude, and independent predictors of TCM use among PD patients. To expand the prevalence of TCM use among patients with PD, we recommend to broadening the public outreach for TCM via contemporary means of Internet and broadcast communication, enhancing access to TCM services in rural communities, and strengthening the communication between doctors and patients.</p><p>Please cite this article as: Wang P, Hong J, Tang ZQ, Gong BZ, Qi XR, Jiang H, Pan B, Chen Q. The acceptance of traditional Chinese medicine among patients with Parkinson’s disease: A hospital survey. <em>J Integr Med</em>. 2024; 22(2): 180–187.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 2","pages":"Pages 180-187"},"PeriodicalIF":4.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140075299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.joim.2023.11.006
Zheng-gang Zhu , Jian-ru Wang , Xiao-yan Pan
<div><h3>Background</h3><p>Scraping therapy is widely used in treating stage I and II essential hypertension in China. However, there has been no systematic evaluation of the efficacy of scraping therapy on blood pressure and sleep quality in stage I and II essential hypertension.</p></div><div><h3>Search strategy</h3><p>Seven electronic databases (PubMed, Scopus, Cochrane Library, Web of Science, EBSCO, China National Knowledge Infrastructure and Wanfang Data electronic databases) were searched from inception to December 2022. Based on the principle of combining subject words with text words, the search strategy was constructed around search terms for “scraping therapy,” “scraping,” “<em>Guasha</em>,” “<em>Gua sha</em>,” “hypertension,” and “high blood pressure” during the database searches.</p></div><div><h3>Inclusion criteria</h3><p>Randomized controlled trials (RCTs) were included if they recruited patients with stage I and II essential hypertension and included a scraping therapy intervention. The intervention group received antihypertensive drugs and scraping therapy, while the control group only took antihypertensive drugs.</p></div><div><h3>Data extraction and analysis</h3><p>Review Manager 5.4.0 and STATA 15.1 were used to enter all the relevant outcome variables to conduct the meta-analysis. The quality of the selected RCTs was assessed using the PEDro scale. The sensitivity analysis was carried out by iteratively excluding individual studies and repeating the analysis to determine the stability of the findings and identify any studies with greater influence on the outcome. Subgroup analysis was performed to find the source of heterogeneity. Funnel plots were used to evaluate the publication bias of included studies.</p></div><div><h3>Results</h3><p>Nine RCTs including 765 participants were selected. Meta-analysis showed that scraping therapy combined with medication had an advantage over the use of medication alone in lowering systolic blood pressure (mean difference [MD] = −5.09, 95% confidence interval [CI] = −6.50 to −3.67, <em>P</em> < 0.001) and diastolic blood pressure (MD = −2.66, 95% CI = −3.17 to −2.14, <em>P</em> < 0.001). Subgroup analysis showed that scraping therapy improved sleep quality in middle-aged patients with hypertension, but the efficacy was better in elderly patients (MD = −7.91, 95% CI = −8.65 to −7.16, <em>P</em> < 0.001) than in middle-aged patients (MD = −2.67, 95% CI = −4.12 to −1.21, <em>P</em> = 0.0003).</p></div><div><h3>Conclusion</h3><p>The available evidence indicates that scraping therapy has significant effects on patients with stage I and II hypertension, and it improves sleep quality for elderly patients with hypertension better than for middle-aged ones. Scraping therapy can be an adjunctive treatment for stage I and II essential hypertension. However, further high-quality studies are needed to verify its effectiveness and the best therapeutic strategies.</p><p>Please cite this article a
背景刮痧疗法在中国广泛应用于治疗I期和II期原发性高血压。然而，目前还没有系统的评价刮痧疗法对I期和II期原发性高血压患者血压和睡眠质量的影响。检索策略:检索自成立至2022年12月的7个电子数据库(PubMed、Scopus、Cochrane Library、Web of Science、EBSCO、中国知网和万方数据电子数据库)。基于主题词与文本词相结合的原则，在数据库搜索过程中围绕“刮痧疗法”、“刮痧”、“瓜沙”、“瓜沙”、“高血压”、“高血压”等搜索词构建搜索策略。纳入标准:纳入随机对照试验(RCTs)，如果他们招募了I期和II期原发性高血压患者，并包括刮痧治疗干预。干预组给予降压药和刮痧治疗，对照组只服用降压药。数据提取与分析:使用Review Manager 5.4.0和STATA 15.1输入所有相关结局变量进行meta分析。采用PEDro量表对所选随机对照试验的质量进行评估。敏感性分析是通过反复排除个别研究并重复分析来确定结果的稳定性并确定对结果影响较大的研究来进行的。进行亚组分析以寻找异质性的来源。采用漏斗图评价纳入研究的发表偏倚。结果共纳入9项随机对照试验，共纳入受试者765人。meta分析显示，刮痧疗法联合药物治疗在降低收缩压方面优于单独使用药物治疗(平均差值[MD] = -5.09, 95%可信区间[CI] = -6.50 ~ -3.67, P <0.001)和舒张压(MD = -2.66, 95% CI = -3.17 ~ -2.14, P <0.001)。亚组分析显示，刮痧疗法改善了中年高血压患者的睡眠质量，但老年患者的效果更好(MD = -7.91, 95% CI = -8.65 ~ -7.16, P <0.001)高于中年患者(MD = -2.67, 95% CI = -4.12 ~ -1.21, P = 0.0003)。结论现有证据表明刮痧疗法对ⅰ、ⅱ期高血压患者有显著疗效，且对老年高血压患者睡眠质量的改善效果优于中年高血压患者。刮痧治疗可作为I期和II期原发性高血压的辅助治疗。然而，需要进一步的高质量研究来验证其有效性和最佳治疗策略。这篇文章的署名为:朱志刚，王小杰，潘晓霞。刮痧疗法对I期和II期原发性高血压患者血压和睡眠质量的影响:一项系统综述和荟萃分析。中华医学杂志;2009;打印前Epub。
{"title":"Efficacy of scraping therapy on blood pressure and sleep quality in stage I and II essential hypertension: A systematic review and meta-analysis","authors":"Zheng-gang Zhu , Jian-ru Wang , Xiao-yan Pan","doi":"10.1016/j.joim.2023.11.006","DOIUrl":"10.1016/j.joim.2023.11.006","url":null,"abstract":"<div><h3>Background</h3><p>Scraping therapy is widely used in treating stage I and II essential hypertension in China. However, there has been no systematic evaluation of the efficacy of scraping therapy on blood pressure and sleep quality in stage I and II essential hypertension.</p></div><div><h3>Search strategy</h3><p>Seven electronic databases (PubMed, Scopus, Cochrane Library, Web of Science, EBSCO, China National Knowledge Infrastructure and Wanfang Data electronic databases) were searched from inception to December 2022. Based on the principle of combining subject words with text words, the search strategy was constructed around search terms for “scraping therapy,” “scraping,” “<em>Guasha</em>,” “<em>Gua sha</em>,” “hypertension,” and “high blood pressure” during the database searches.</p></div><div><h3>Inclusion criteria</h3><p>Randomized controlled trials (RCTs) were included if they recruited patients with stage I and II essential hypertension and included a scraping therapy intervention. The intervention group received antihypertensive drugs and scraping therapy, while the control group only took antihypertensive drugs.</p></div><div><h3>Data extraction and analysis</h3><p>Review Manager 5.4.0 and STATA 15.1 were used to enter all the relevant outcome variables to conduct the meta-analysis. The quality of the selected RCTs was assessed using the PEDro scale. The sensitivity analysis was carried out by iteratively excluding individual studies and repeating the analysis to determine the stability of the findings and identify any studies with greater influence on the outcome. Subgroup analysis was performed to find the source of heterogeneity. Funnel plots were used to evaluate the publication bias of included studies.</p></div><div><h3>Results</h3><p>Nine RCTs including 765 participants were selected. Meta-analysis showed that scraping therapy combined with medication had an advantage over the use of medication alone in lowering systolic blood pressure (mean difference [MD] = −5.09, 95% confidence interval [CI] = −6.50 to −3.67, <em>P</em> < 0.001) and diastolic blood pressure (MD = −2.66, 95% CI = −3.17 to −2.14, <em>P</em> < 0.001). Subgroup analysis showed that scraping therapy improved sleep quality in middle-aged patients with hypertension, but the efficacy was better in elderly patients (MD = −7.91, 95% CI = −8.65 to −7.16, <em>P</em> < 0.001) than in middle-aged patients (MD = −2.67, 95% CI = −4.12 to −1.21, <em>P</em> = 0.0003).</p></div><div><h3>Conclusion</h3><p>The available evidence indicates that scraping therapy has significant effects on patients with stage I and II hypertension, and it improves sleep quality for elderly patients with hypertension better than for middle-aged ones. Scraping therapy can be an adjunctive treatment for stage I and II essential hypertension. However, further high-quality studies are needed to verify its effectiveness and the best therapeutic strategies.</p><p>Please cite this article a","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 1","pages":"Pages 12-21"},"PeriodicalIF":4.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2095496423000973/pdfft?md5=23b8e0f4bf71e751cc92063998c6a344&pid=1-s2.0-S2095496423000973-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138496866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.joim.2024.01.002
Maria Younes, Ghady Loubnane, Christopher Sleiman, Sandra Rizk
Tocotrienols are found in a variety of natural sources, like rice bran, annatto seeds and palm oil, and have been shown to have several health-promoting properties, particularly against chronic diseases such as cancer. The incidence of cancer is rapidly increasing around the world, not only a result of continued aging and population growth, but also due to the adoption of aspects of the Western lifestyle, such as high-fat diets and low-physical activity. The literature provides strong evidence that tocotrienols are able to inhibit the growth of various cancers, including breast, lung, ovarian, prostate, liver, brain, colon, myeloma and pancreatic cancers. These findings, along with the reported safety profile of tocotrienols in healthy human volunteers, encourage further research into these compounds’ potential use in cancer prevention and treatment. The current review provided detailed information about the molecular mechanisms of action of different tocotrienol isoforms in various cancer models and evaluated the potential therapeutic effects of different vitamin E analogues on important cancer hallmarks, such as cellular proliferation, apoptosis, angiogenesis and metastasis. MEDLINE/PubMed and Scopus databases were used to identify recently published articles that investigated the anticancer effects of vitamin E derivatives in various types of cancer in vitro and in vivo along with clinical evidence of adjuvant chemopreventive benefits. Following an overview of pre-clinical studies, we describe several completed and ongoing clinical trials that are paving the way for the successful implementation of tocotrienols in cancer chemotherapy.
生育三烯酚存在于米糠、红木种子和棕榈油等多种天然来源中，已被证明具有多种促进健康的特性，尤其是针对癌症等慢性疾病。癌症发病率在全球迅速上升，这不仅是老龄化和人口持续增长的结果，也是采用高脂肪饮食和低体力活动等西方生活方式的结果。文献提供的有力证据表明，生育三烯酚能够抑制各种癌症的生长，包括乳腺癌、肺癌、卵巢癌、前列腺癌、肝癌、脑癌、结肠癌、骨髓瘤和胰腺癌。这些发现以及据报道生育三烯酚对健康人体志愿者的安全性，鼓励人们进一步研究这些化合物在癌症预防和治疗中的潜在用途。本综述详细介绍了不同生育三烯酚异构体在各种癌症模型中的分子作用机制，并评估了不同维生素 E 类似物对重要癌症标志（如细胞增殖、凋亡、血管生成和转移）的潜在治疗效果。研究人员利用 MEDLINE/PubMed 和 Scopus 数据库，查找了近期发表的研究维生素 E 衍生物对各类癌症的体外和体内抗癌作用的文章，以及辅助化学预防作用的临床证据。在概述了临床前研究之后，我们介绍了几项已经完成和正在进行的临床试验，这些试验为在癌症化疗中成功应用生育三烯酚铺平了道路。
{"title":"Tocotrienol isoforms: The molecular mechanisms underlying their effects in cancer therapy and their implementation in clinical trials","authors":"Maria Younes, Ghady Loubnane, Christopher Sleiman, Sandra Rizk","doi":"10.1016/j.joim.2024.01.002","DOIUrl":"10.1016/j.joim.2024.01.002","url":null,"abstract":"<div><p><span>Tocotrienols<span> are found in a variety of natural sources, like rice bran, annatto seeds and palm oil, and have been shown to have several health-promoting properties, particularly against chronic diseases such as cancer. The incidence of cancer is rapidly increasing around the world, not only a result of continued aging and population growth, but also due to the adoption of aspects of the Western lifestyle, such as high-fat diets and low-physical activity. The literature provides strong evidence that tocotrienols are able to inhibit the growth of various cancers, including breast, lung, ovarian, prostate, liver, brain, colon, myeloma<span><span><span> and pancreatic cancers. These findings, along with the reported safety profile of tocotrienols in healthy human volunteers, encourage further research into these compounds’ potential use in cancer prevention and treatment. The current review provided detailed information about the molecular mechanisms of action of different tocotrienol isoforms in various cancer models and evaluated the potential therapeutic effects of different </span>vitamin E<span><span> analogues on important cancer hallmarks, such as cellular proliferation, </span>apoptosis<span>, angiogenesis<span> and metastasis. MEDLINE/PubMed and Scopus databases were used to identify recently published articles that investigated the anticancer effects of </span></span></span></span>vitamin E derivatives in various types of cancer in vitro and in vivo along with clinical evidence of adjuvant chemopreventive benefits. Following an overview of pre-clinical studies, we describe several completed and ongoing </span></span></span>clinical trials<span> that are paving the way for the successful implementation of tocotrienols in cancer chemotherapy.</span></p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 1","pages":"Pages 1-11"},"PeriodicalIF":4.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139499404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.joim.2023.12.001
Yue-ying Ma , Zhou Hao , Zi-yi Chen , Yan-xi Shen , Hui-rong Liu , Huan-gan Wu , Chun-hui Bao
<div><h3>Background</h3><p>Irritable bowel syndrome (IBS) is a functional bowel disease characterized by abdominal pain or discomfort associated with altered bowel habits. Several clinical studies have demonstrated the effectiveness of acupuncture and moxibustion for IBS. Many systematic reviews of acupuncture and moxibustion for IBS have been published in recent years, but their results are not entirely consistent.</p></div><div><h3>Objective</h3><p>To evaluate the methodological, reporting, and evidence quality of systematic reviews of acupuncture and moxibustion for IBS.</p></div><div><h3>Search strategy</h3><p>Systematic reviews of acupuncture and moxibustion for IBS published before February 20, 2023 were searched in eight databases: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Data, VIP Database for Chinese Technical Periodicals, and China Biology Medicine. The keywords used for literature search were acupuncture, moxibustion, systematic review, meta-analysis, and irritable bowel syndrome.</p></div><div><h3>Inclusion criteria</h3><p>Systematic reviews and meta-analyses of randomized controlled trials of acupuncture and moxibustion for IBS were included.</p></div><div><h3>Data extraction and analysis</h3><p>Relevant information was independently extracted by two investigators. The A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR 2), Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020), and Grading of Recommendations Assessment, Development and Evaluation (GRADE) were used to evaluate the methodological quality, reporting quality and evidence quality, respectively.</p></div><div><h3>Results</h3><p>A total of 342 studies were retrieved and 15 systematic reviews were included. The results of AMSTAR 2 showed low methodological quality in 2 studies and very low methodological quality in the remaining 13 studies, with main issues being failure to register a protocol, incomplete search strategy, not providing a list of excluded studies, incomplete consideration of the risk of bias in the included studies, and a failure to assess the publication bias. The results of PRISMA 2020 showed seriously deficient reporting quality of 2 studies, somewhat deficient reporting quality of 12 studies, and relatively complete reporting quality of 1 study, with the main problems being lack of a complete search strategy, non-availability of a list of excluded studies with justification for their exclusion, not conducting heterogeneity and sensitivity analyses, not evaluating the credibility of the evidence, and not registering the protocol. The results of GRADE showed that the quality of the evidence is low or very low.</p></div><div><h3>Conclusion</h3><p>Most included systematic reviews interpreted findings to suggest that acupuncture and moxibustion have benefits for IBS. However, there is a need to improve the methodological, reporting and evidence quality of the systematic
{"title":"Acupuncture and moxibustion for irritable bowel syndrome: An umbrella systematic review","authors":"Yue-ying Ma , Zhou Hao , Zi-yi Chen , Yan-xi Shen , Hui-rong Liu , Huan-gan Wu , Chun-hui Bao","doi":"10.1016/j.joim.2023.12.001","DOIUrl":"10.1016/j.joim.2023.12.001","url":null,"abstract":"<div><h3>Background</h3><p>Irritable bowel syndrome (IBS) is a functional bowel disease characterized by abdominal pain or discomfort associated with altered bowel habits. Several clinical studies have demonstrated the effectiveness of acupuncture and moxibustion for IBS. Many systematic reviews of acupuncture and moxibustion for IBS have been published in recent years, but their results are not entirely consistent.</p></div><div><h3>Objective</h3><p>To evaluate the methodological, reporting, and evidence quality of systematic reviews of acupuncture and moxibustion for IBS.</p></div><div><h3>Search strategy</h3><p>Systematic reviews of acupuncture and moxibustion for IBS published before February 20, 2023 were searched in eight databases: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Data, VIP Database for Chinese Technical Periodicals, and China Biology Medicine. The keywords used for literature search were acupuncture, moxibustion, systematic review, meta-analysis, and irritable bowel syndrome.</p></div><div><h3>Inclusion criteria</h3><p>Systematic reviews and meta-analyses of randomized controlled trials of acupuncture and moxibustion for IBS were included.</p></div><div><h3>Data extraction and analysis</h3><p>Relevant information was independently extracted by two investigators. The A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR 2), Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020), and Grading of Recommendations Assessment, Development and Evaluation (GRADE) were used to evaluate the methodological quality, reporting quality and evidence quality, respectively.</p></div><div><h3>Results</h3><p>A total of 342 studies were retrieved and 15 systematic reviews were included. The results of AMSTAR 2 showed low methodological quality in 2 studies and very low methodological quality in the remaining 13 studies, with main issues being failure to register a protocol, incomplete search strategy, not providing a list of excluded studies, incomplete consideration of the risk of bias in the included studies, and a failure to assess the publication bias. The results of PRISMA 2020 showed seriously deficient reporting quality of 2 studies, somewhat deficient reporting quality of 12 studies, and relatively complete reporting quality of 1 study, with the main problems being lack of a complete search strategy, non-availability of a list of excluded studies with justification for their exclusion, not conducting heterogeneity and sensitivity analyses, not evaluating the credibility of the evidence, and not registering the protocol. The results of GRADE showed that the quality of the evidence is low or very low.</p></div><div><h3>Conclusion</h3><p>Most included systematic reviews interpreted findings to suggest that acupuncture and moxibustion have benefits for IBS. However, there is a need to improve the methodological, reporting and evidence quality of the systematic ","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 1","pages":"Pages 22-31"},"PeriodicalIF":4.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2095496423000985/pdfft?md5=9c757eeab4d5876b083f9640ef681246&pid=1-s2.0-S2095496423000985-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139028503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号